Centessa Pharmaceuticals Management
Management criteria checks 2/4
Centessa Pharmaceuticals' CEO is Saurabh Saha, appointed in Jan 2021, has a tenure of 3.83 years. total yearly compensation is $2.71M, comprised of 24.1% salary and 75.9% bonuses, including company stock and options. directly owns 0.4% of the company’s shares, worth €8.92M. The average tenure of the management team and the board of directors is 1.3 years and 3.8 years respectively.
Key information
Saurabh Saha
Chief executive officer
US$2.7m
Total compensation
| CEO salary percentage | 24.1% |
| CEO tenure | 3.8yrs |
| CEO ownership | 0.4% |
| Management average tenure | 1.3yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$161m |
| Jun 30 2024 | n/a | n/a | -US$157m |
| Mar 31 2024 | n/a | n/a | -US$138m |
| Dec 31 2023 | US$3m | US$652k | -US$151m |
| Sep 30 2023 | n/a | n/a | -US$157m |
| Jun 30 2023 | n/a | n/a | -US$173m |
| Mar 31 2023 | n/a | n/a | -US$212m |
| Dec 31 2022 | US$10m | US$621k | -US$216m |
| Sep 30 2022 | n/a | n/a | -US$234m |
| Jun 30 2022 | n/a | n/a | -US$220m |
| Mar 31 2022 | n/a | n/a | -US$197m |
| Dec 31 2021 | US$16m | US$573k | -US$381m |
Compensation vs Market: Saurabh's total compensation ($USD2.71M) is above average for companies of similar size in the German market ($USD1.66M).
Compensation vs Earnings: Saurabh's compensation has been consistent with company performance over the past year.
CEO
Saurabh Saha (48 yo)
3.8yrs
Tenure
US$2,705,874
Compensation
Dr. Saurabh Saha, M. D., Ph. D. serves as an Independent Director at Clarivate Plc since May 04, 2023. He serves as the Chief Executive Officer at Centessa Pharmaceuticals plc (formerly Centessa Pharmaceut...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.8yrs | US$2.71m | 0.40% € 8.9m | |
| Chief Administrative Officer | 3.6yrs | US$1.32m | 0.10% € 2.3m | |
| CFO and Principal Financial & Accounting Officer | less than a year | no data | no data | |
| Chief Technology & Quality Officer | 1.3yrs | no data | 0.059% € 1.3m | |
| Senior Vice President of Investor Relations & Corporate Communications | 2.4yrs | no data | no data | |
| General Counsel | 3.8yrs | no data | 0.071% € 1.6m | |
| Chief People Officer | 2yrs | no data | 0.054% € 1.2m | |
| Chief Business Officer | less than a year | US$3.31m | 0.054% € 1.2m | |
| President of the Orexin Program | less than a year | no data | no data | |
| Senior Vice President of Clinical Development & Oncology | 1.1yrs | no data | no data | |
| Senior Vice President of Clinical Development Operations | less than a year | no data | no data |
1.3yrs
Average Tenure
53yo
Average Age
Experienced Management: 260's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.8yrs | US$2.71m | 0.40% € 8.9m | |
| Independent Non-Executive Chairman of the Board | 4yrs | no data | no data | |
| Independent Non-Executive Director | 3.8yrs | US$252.69k | 0% € 0 | |
| Independent Non-Executive Director | 3.8yrs | US$257.69k | 0% € 0 | |
| Independent Non-Executive Director | 3.8yrs | US$260.19k | 0% € 0 | |
| Independent Non-Executive Director | 3.8yrs | US$255.19k | 0% € 0 | |
| Independent Non-Executive Director | 3.5yrs | US$262.69k | 0% € 0 | |
| Independent Non-Executive Director | 2.3yrs | US$247.69k | 0% € 0 |
3.8yrs
Average Tenure
53yo
Average Age
Experienced Board: 260's board of directors are considered experienced (3.8 years average tenure).